Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules
To read the full story
Related Article
- Bosulif, 4 Other Drugs Escape April Re-Pricing as “Spillover” Scrapped; Lixiana, Entresto Brace for Cuts
January 19, 2026
- FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair
January 6, 2026
- Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
- Trade Groups Hail Spillover Abolition, but Urge Further Overhauls
December 26, 2025
- Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
REGULATORY
- MHLW Eyes Bigger Push for Regional Formularies in FY2030–FY2035 Cost Plan
November 18, 2026
- Japan Approves Boey, Wider Labels for Hernexeos, Rinvoq, Tukysa, Pluvicto, and More
November 17, 2026
- Novartis Sjögren’s Drug, Meiji Antibiotic and More Up for Nov. 30 Panel Review
November 17, 2026
- Japan Grants Orphan Status to Rusfertide, Surovatamig, and Lots More
November 17, 2026
- Japan Extends Re-Examination for Saphnelo, Airwin, Fabhalta, Uplizna
November 17, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





